Published in J Allergy Clin Immunol on April 01, 1998
External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax (2006) 1.72
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ (2001) 1.67
Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax (2002) 1.28
Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax (1999) 1.21
A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid. Ther Clin Risk Manag (2007) 0.99
Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res (2004) 0.86
Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. AAPS PharmSciTech (2009) 0.86
Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract (2007) 0.84
Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax (2005) 0.82
Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax (2002) 0.82
Chronic asthma. BMJ (2001) 0.81
Use of sequential quadrupling dose regimens to study efficacy of inhaled corticosteroids in asthma. Thorax (2004) 0.81
Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study. Respir Res (2012) 0.81
Inhaled Corticosteroids. Pharmaceuticals (Basel) (2010) 0.79
Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol (1975) 10.52
Acute respiratory distress in adults. Lancet (1967) 9.06
Complications and consequences of endotracheal intubation and tracheotomy. A prospective study of 150 critically ill adult patients. Am J Med (1981) 6.23
Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax (2003) 4.81
Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med (2000) 3.79
Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med (1983) 3.79
The role of long-term continuous oxygen administration in patients with chronic airway obstruction with hypoxemia. Ann Intern Med (1967) 2.10
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med (1992) 2.10
Long-term continuous oxygen therapy in chronic airway obstruction. Mortality in relationship to cor pulmonale, hypoxia, and hypercapnia. Ann Intern Med (1970) 2.06
The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. Chest (1971) 2.03
The use of corticosteroids in the treatment of respiratory failure associated with massive fat embolism. Surg Gynecol Obstet (1966) 1.90
Continuous positive-pressure breathing (CPPB) in adult respiratory distress syndrome. J Thorac Cardiovasc Surg (1969) 1.86
Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med (1998) 1.85
Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science (1981) 1.80
Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis (1989) 1.76
A comprehensive care program for chronic airway obstruction. Methods and preliminary evaluation of symptomatic and functional improvement. Ann Intern Med (1969) 1.68
Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects. J Allergy Clin Immunol (1975) 1.68
Endobronchial tuberculosis progressing to bronchial stenosis. Fiberoptic bronchoscopic manifestations. Chest (1976) 1.65
Positive end-expiratory pressure. Physiology, indications, and contraindications. J Thorac Cardiovasc Surg (1973) 1.64
Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med (1968) 1.63
Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med (1983) 1.55
Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) (1975) 1.54
Physical, symptomatic and psychological improvement in patients receiving comprehensive care for chronic airway obstruction. J Chronic Dis (1971) 1.53
Early detection for lung cancer. New tools for casefinding. Can Fam Physician (2001) 1.51
Outcome of 51 patients with roentgenographically occult lung cancer detected by sputum cytologic testing: a community hospital program. Arch Intern Med (1994) 1.51
Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med (1999) 1.50
Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev (2011) 1.50
Ventilation and arterial blood gas changes induced by pursed lips breathing. J Appl Physiol (1970) 1.48
Genetic analysis of allergic disease in twins. J Allergy Clin Immunol (1984) 1.46
Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. Thorax (2010) 1.46
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol (1999) 1.46
Clinical evaluation of prolonged ambulatory oxygen therapy in chronic airway obstruction. Am J Med (1968) 1.45
Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol (1995) 1.43
Complications of assisted ventilation. A prospective study of 354 consecutive episodes. Am J Med (1974) 1.42
COPD exacerbations: the importance of a standard definition. Respir Med (2004) 1.42
The significance of morphologic chronic hyperplastic bronchitis. Am Rev Respir Dis (1966) 1.40
Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J (1998) 1.39
The forgotten vital signs. Hosp Pract (Off Ed) (1994) 1.39
The pulmonary academic "transitional track". How do we get them out of the nest? Am Rev Respir Dis (1989) 1.39
Objective functional improvement in chronic airway obstruction. Chest (1970) 1.38
Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. J Allergy Clin Immunol (1997) 1.38
Early diagnosis of COPD. Hosp Pract (1995) (2001) 1.38
Addressing oral disease--the case for tobacco cessation services. J Can Dent Assoc (2001) 1.38
Home oxygen therapy for COPD: practical aspects. Postgrad Med (1981) 1.37
The presence of airway reactivity before the development of asthma. Am Rev Respir Dis (1990) 1.32
Endobronchial tuberculosis. Chest (1973) 1.27
Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest (1980) 1.22
Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol (1996) 1.21
Obstructive lung disease in hereditary alpha 1-antitrypsin deficiency. JAMA (1970) 1.19
Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med (1992) 1.19
Outpatient oxygen therapy in chronic obstructive pulmonary disease. A review of 13 years' experience and an evaluation of modes of therapy. Arch Intern Med (1979) 1.18
Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis. Arch Intern Med (1979) 1.17
Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA (2001) 1.17
Synthesis of fibronectin, laminin, and several collagens by a liver-derived epithelial line. Lab Invest (1980) 1.16
Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol (1999) 1.15
Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med (1995) 1.14
Difference between lung and spleen susceptibility of beta-adrenergic receptors to desensitization by terbutaline. J Allergy Clin Immunol (1983) 1.14
A program for transtracheal oxygen delivery. Assessment of safety and efficacy. Ann Intern Med (1987) 1.13
Transtracheal oxygen therapy for refractory hypoxemia. JAMA (1986) 1.12
Segregation analysis of bronchial response to methacholine inhalation challenge in families with and without asthma. J Allergy Clin Immunol (1986) 1.11
Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med (1993) 1.10
Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis (1977) 1.10
The effect of age on methacholine response. J Allergy Clin Immunol (1985) 1.09
Effect of hydrocortisone on beta-adrenergic receptors in lung membranes. Life Sci (1979) 1.08
Status asthmaticus. A nine-year experience. JAMA (1977) 1.08
Innovative life support in the acute respiratory distress syndrome. JAMA (1996) 1.07
Retracted Effects of platelet activating factor on cyclic AMP accumulation in human lymphocytes. Ann Allergy (1992) 1.07
Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest (2001) 1.07
Notice of retraction. Effects of platelet activating factor on cyclic AMP accumulation in human lymphocytes. Ann Allergy (1992) 1.07
Interpretation of the results of methacholine inhalation challenge tests. J Allergy Clin Immunol (1987) 1.06
Home oxygen in advanced chronic obstructive pulmonary disease. Med Clin North Am (1981) 1.06
Mycobacterial antigens attenuate late phase response, airway hyperresponsiveness, and bronchoalveolar lavage eosinophilia in a mouse model of bronchial asthma. Int Immunopharmacol (2001) 1.05
Editorial: A critical look at IPPB. Chest (1974) 1.05
Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics (2000) 1.04
Cystic fibrosis gene mutation in two sisters with mild disease and normal sweat electrolyte levels. N Engl J Med (1991) 1.03
Smoking cessation is associated with an increase in exhaled nitric oxide. Chest (1997) 1.03
Duration and specificity of sodium cromolyn on allergen inhalation challenges in asthmatics. J Allergy Clin Immunol (1974) 1.03
Comparison of respiratory and cardiovascular effects of isoproterenol, propranolol, and practolol in asthmatic and normal subjects. J Allergy Clin Immunol (1976) 1.03
Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance. JAMA (1976) 1.02
Methacholine inhalation challenge studies in a selected pediatric population. Am Rev Respir Dis (1986) 1.02
Effect of terfenadine on the bronchoconstriction induced by ultrasonically nebulized distilled water. Ann Allergy (1988) 1.02
Small airway pathology is related to increased closing capacity and abnormal slope of phase III in excised human lungs. Am Rev Respir Dis (1980) 1.02
Apples and oranges : flaws and guffaws. Chest (1999) 1.02
Pulmonary effects of chronic exposure to airborne cadmium. Am Rev Respir Dis (1976) 1.02
Clinical evaluation of a new electronic spirometer. Chest (1973) 1.01
Reinforcing breath carbon monoxide reductions in chronic obstructive pulmonary disease. Drug Alcohol Depend (1991) 1.01
Measurement of exhaled nitric oxide by three different techniques. Am J Respir Crit Care Med (1996) 1.00
Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med (1997) 1.00
The simplicity and safety of arterial puncture. JAMA (1966) 1.00
Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest (1993) 1.00
Mechanisms of neutrophil recruitment to the lung by grain dust exposure. Am Rev Respir Dis (1988) 0.99
The five manifestations of rheumatoid lung. Dis Chest (1966) 0.98
Long-term follow-up and bronchial reactivity testing in survivors of the adult respiratory distress syndrome. Am Rev Respir Dis (1978) 0.97
Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. Chest (1979) 0.97
Consensus conference on problems in home mechanical ventilation. Am Rev Respir Dis (1989) 0.97
Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. J Fam Pract (1996) 0.96
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med (1999) 0.96
Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol (1999) 0.96
Another look at ARDS. Chest (1982) 0.96